2025
Drug interactions in people with HIV treated with antivirals for other viral illnesses
Okoli A, Ogbuagu O. Drug interactions in people with HIV treated with antivirals for other viral illnesses. Expert Opinion On Drug Metabolism & Toxicology 2025, 21: 383-397. PMID: 39836520, PMCID: PMC12169512, DOI: 10.1080/17425255.2025.2455401.Peer-Reviewed Original ResearchDrug-drug interactionsDrug interactionsManagement of drug interactionsTreatment of HIVViral coinfectionAntiviral therapyHepatitis CViral illnessHIV treatmentIncreased riskPrescribing informationEffective treatmentViral infectionHIVAntiviral agentsConference abstractsPWHPatient outcomesARVDrug prescribing informationTreatmentCoinfectionGoogle ScholarDrugMetabolic pathways
2024
Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study
Lewis N, Harker E, Grant L, Zhu Y, Grijalva C, Chappell J, Rhoads J, Baughman A, Casey J, Blair P, Jones I, Johnson C, Lauring A, Gaglani M, Ghamande S, Columbus C, Steingrub J, Shapiro N, Duggal A, Busse L, Felzer J, Prekker M, Peltan I, Brown S, Hager D, Gong M, Mohamed A, Exline M, Khan A, Hough C, Wilson J, Mosier J, Qadir N, Chang S, Ginde A, Martinez A, Mohr N, Mallow C, Harris E, Johnson N, Srinivasan V, Gibbs K, Kwon J, Vaughn I, Ramesh M, Safdar B, Goyal A, DeLamielleure L, DeCuir J, Surie D, Dawood F, Tenforde M, Uyeki T, Garg S, Ellington S, Self W, Gaglani M, McNeal T, Calhoun S, Murthy K, Cravens J, Herrick J, McKillop A, Hoffman E, Graves A, Zayed M, Smith M, Gaglani M, Columbus C, Bychkowski A, Dunkley S, Fisher T, Grefsrud T, Hurutado-Rodriguez M, Perez G, Busse L, Lohuis C, Felzer J, Prekker M, Hendrickson A, Frosch A, Taghizadeh L, Hurreh K, O'Rourke M, Giles L, Vaughn I, Ramesh M, Lamerato L, Almawri K, Atkins I, Clark J, Lava J, McKeon C, Pinderi Z, Resk M, Koneru S, Jayaprakash R, Tirumala S, Williams K, Peltan I, Lumpkin J, Poulson S, Bassett J, Thumma V, Hager D, Ali H, Richard, Saeed S, Mohr N, Zepeski A, Nassar P, Hampton J, Fairfield C, Gibbs H, Feitsam C, Appleton I, Gong M, Mohamed A, Andrea L, Exline M, Karow S, Swoope G, So M, Pathak M, Smith D, Wilson R, Lewald Z, Snyder C, Khan M, Lee B, Rasul A, Khan A, Hernandez-Frausto A, Pocius E, Tribbett E, Briceno G, Pena J, Pellicer S, Reddy R, Allada G, Wilson J, Gordon A, Perez C, Lau L, Ferguson S, Pitre V, Tam G, Basobas L, Mosier J, Lutrick K, Hypes C, Campbell B, Ginde A, Martinez A, Steinwand A, Sullivan A, Withers C, Rademacher J, Obradovich R, Mallow C, Rivas C, Johnson N, Acidera J, Elkort K, Gajendragadkar A, McKeown M, Self W, Talbot H, Grijalva C, Blair P, Jones I, Halasa N, Chappell J, Womack K, Rhoads J, Ratcliff C, Baughman A, Johnson J, Swan S, Johnson C, Zhu Y, Rice T, Casey J, Zhu Y, Short L, Ezzell L, Whitsett M, McHenry R, Hargrave S, Luther J, Pulido C, Peterson B, Cummings S, Gauthier E, Jackson A, Rashid N, Blair M, Rice C, Kwon J, Parikh B, McDonald D, Samuels C, Vogt L, O'Neil C, Valencia A, Yerbic F, Arter O, Vu K, Safdar B, Goyal A, DeLamielleure L, Kosover M. Benefit of Early Oseltamivir Therapy for Adults Hospitalized With Influenza A: An Observational Study. Clinical Infectious Diseases 2024, ciae584. PMID: 39607747, DOI: 10.1093/cid/ciae584.Peer-Reviewed Original ResearchDays of hospital admissionPulmonary disease severityKidney replacement therapyIn-Hospital DeathIntensive care unitDay of admissionOseltamivir treatmentVasopressor useReplacement therapyInitiation of antiviral therapyOdds of intensive care unit admissionAcute kidney replacement therapyExtrapulmonary organ failureInfluenza-positive patientsLaboratory-confirmed influenzaIntensive care unit admissionDisease severityHospital admissionMultivariate logistic regression modelSentinel Surveillance NetworkOseltamivir therapySuspected influenzaInfluenza AAntiviral therapyMultivariable proportional odds modelAssociation of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma
Yang Z, Cheung R, Jou J, Lim J, Lim Y, Wong R. Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma. Gastroenterology Research 2024, 17: 109-115. PMID: 38993547, PMCID: PMC11236339, DOI: 10.14740/gr1735.Peer-Reviewed Original ResearchBaseline HBV DNARisk of hepatocellular carcinomaChronic hepatitis BRisk of cirrhosisNon-cirrhotic chronic hepatitis BHepatitis B virus DNAHBV DNAHepatocellular carcinomaHepatitis B virusCHB patientsPropensity score weightingAntiviral therapyAssociated with higher risk of hepatocellular carcinomaHigh risk of hepatocellular carcinomaNon-cirrhotic CHB patientsCohort of CHB patientsLevels of hepatitis B virusContinuous antiviral therapyHigh HBV DNANon-Asian cohortModerate levelsAssociated with higher riskScore weightingB virus DNACox proportional hazards modelsClinical Characteristics and Outcomes of Unvaccinated Kidney Transplant Recipients Infected with the SARS-CoV-2 Omicron Variant: A Case Series
Qu Y, Zhuang J, Duan Y, Baibutihan A, Maimaiti Z, Zhang C, Niu J, Teng W, Ailimu M, Wei X, Qi B, Li J, Du S, Wang D, Cao K, Wang J, Lu C, Tian X, Jiang H. Clinical Characteristics and Outcomes of Unvaccinated Kidney Transplant Recipients Infected with the SARS-CoV-2 Omicron Variant: A Case Series. Integrative Medicine In Nephrology And Andrology 2024, 11: e00019. DOI: 10.1097/imna-d-23-00019.Peer-Reviewed Original ResearchKidney transplant recipientsKT recipientsClinical characteristicsKidney transplantationTransplant recipientsElevated serum D-dimerIncidence of severe infectionsOmicron infectionSevere/critical illnessOutcomes of severe acute respiratory syndrome coronavirus 2Calcineurin inhibitor drugsSerum D-dimerSerum albumin levelSARS-CoV-2Acute kidney injuryFollow-up periodC-reactive proteinSARS-CoV-2 Omicron infectionSARS-CoV-2 Omicron variantReverse transcription polymerase chain reactionImmunocompromised statusFerritin levelsTranscription polymerase chain reactionSevere/critical groupAntiviral therapy
2023
Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy
Cartwright E, Pierret C, Minassian C, Esserman D, Tate J, Goetz M, Bhattacharya D, Fiellin D, Justice A, Re V, Rentsch C. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy. JAMA Network Open 2023, 6: e2335715. PMID: 37751206, PMCID: PMC10523171, DOI: 10.1001/jamanetworkopen.2023.35715.Peer-Reviewed Original ResearchConceptsSustained virologic responseAlcohol use disorderHigh-risk consumptionHistory of AUDLow-risk consumptionDAA therapyAlcohol use categoriesAlcohol useVirologic responseCohort studyAntiviral therapyOdds ratioChronic hepatitis C virus (HCV) infectionAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionVeterans AffairsActing antiviral (DAA) therapyDAA treatment initiationHCV elimination goalsUndetectable HCV RNAC virus infectionFibrosis-4 scoreRetrospective cohort studyMultivariable logistic regressionTenth Revision diagnosisAlgorithms for Detection and Identification of Viruses
Landry M, Babady N, Binnicker M, Pinsky B, Tang Y. Algorithms for Detection and Identification of Viruses. 2023, 1-5. DOI: 10.1002/9781683674849.mcm0084.Peer-Reviewed Original ResearchIntroduction of nucleic acid amplification testingNucleic acid amplification testsRespiratory viral culturesSexually transmitted virusDetection of viral antigensDevelopment of antiviral therapiesImmunosuppressed hostsViral cultureAntiviral therapyRoutine cultureClinical specimensAmplification testsCentrifugation cultureViral antigensEnzyme immunoassayMonoclonal antibodiesDiagnostic virologyIdentification of virusesCapture assayCoronavirus diseaseVirusEmergence of epidemicsMedical careIncreasing numberTherapyAlgorithms for Detection and Identification of Viruses
Landry M, Babady N, Binnicker M, Pinsky B, Tang Y. Algorithms for Detection and Identification of Viruses. 2023, 1-5. DOI: 10.1002/9781683670438.mcm0084.Peer-Reviewed Original ResearchIntroduction of nucleic acid amplification testingNucleic acid amplification testsRespiratory viral culturesSexually transmitted virusDetection of viral antigensDevelopment of antiviral therapiesImmunosuppressed hostsViral cultureAntiviral therapyRoutine cultureClinical specimensAmplification testsCentrifugation cultureViral antigensEnzyme immunoassayMonoclonal antibodiesDiagnostic virologyIdentification of virusesCapture assayCoronavirus diseaseVirusEmergence of epidemicsMedical careIncreasing numberTherapy
2021
Treatment and prevention of viral hepatitis in pregnancy
Dionne-Odom J, Cozzi GD, Franco RA, Njei B, Tita ATN. Treatment and prevention of viral hepatitis in pregnancy. American Journal Of Obstetrics And Gynecology 2021, 226: 335-346. PMID: 34516961, PMCID: PMC8907340, DOI: 10.1016/j.ajog.2021.09.002.Peer-Reviewed Original ResearchConceptsHepatitis BViral hepatitisHepatitis AHepatitis CAntiviral therapyPregnant womenVertical transmissionImmunoglobulin GActive hepatitis BBirth dose vaccineChronic viral hepatitisHigh clinical suspicionBlood-borne transmissionElevated viral loadRisk of acquisitionVertical transmission riskMedical history reviewTenofovir disoproxil fumarateAcquisition of infectionFecal-oral transmissionRoutine prenatal screeningRoute of infectionHerpes simplex virusVaccine seriesCesarean deliveryO-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES
Ragazzo T, Garcia-Tsao G, Mazo D, Ziteli P, Oliveira C, Singer J, Carrilho F, Pessoa M. O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES. Annals Of Hepatology 2021, 24: 100493. DOI: 10.1016/j.aohep.2021.100493.Peer-Reviewed Original ResearchLiver stiffness measurementF3/F4Viral eliminationLiver fibrosisF0-1Advanced liver fibrosis/cirrhosisLiver fibrosis/cirrhosisChronic liver diseaseFibrosis/cirrhosisNon-invasive testsNon-invasive assessmentHCV cureAntiviral therapyClinical outcomesLiver diseaseHepatic fibrosisClinical usefulnessPatientsPredictive valueRelevant outcomesDecompensationLarger studyFibrosisLSM increaseStiffness measurementTransplant Adenovirus Infection: Clinical Syndromes, Diagnosis, and Management
Malinis M, Azar M. Transplant Adenovirus Infection: Clinical Syndromes, Diagnosis, and Management. 2021, 781-805. DOI: 10.1007/978-3-030-25869-6_33.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSolid organ transplant recipientsInadequate clinical responseReduction of immunosuppressionCornerstone of treatmentOrgan transplant recipientsSolid organ transplantationManifestations of diseaseDirect antigen detectionGraft dysfunctionGraft lossImmunosuppression reductionTransplant recipientsClinical responseAntiviral therapySignificant morbidityAsymptomatic sheddingTherapeutic optionsViral cultureClinical syndromeAdenoviral diseaseOrgan transplantationHematopoietic stem cellsAntigen detectionAdenovirus infectionInfection
2020
Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2
Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, Yarbrough A, Abzug MJ, MacBrayne CE, Soma VL, Dulek DE, Vora SB, Waghmare A, Wolf J, Olivero R, Grapentine S, Wattier RL, Bio L, Cross SJ, Dillman NO, Downes KJ, Oliveira CR, Timberlake K, Young J, Orscheln RC, Tamma PD, Schwenk HT, Zachariah P, Aldrich ML, Goldman DL, Groves HE, Rajapakse NS, Lamb GS, Tribble AC, Hersh AL, Thorell EA, Denison MR, Ratner AJ, Newland JG, Nakamura MM. Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. Journal Of The Pediatric Infectious Diseases Society 2020, 10: 34-48. PMID: 32918548, PMCID: PMC7543452, DOI: 10.1093/jpids/piaa115.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMechanical ventilationCOVID-19Pediatric infectious disease physiciansInvasive mechanical ventilationSupplemental oxygen requirementInfectious disease physiciansUse of hydroxychloroquineUse of remdesivirNoninvasive mechanical ventilationUse of antiviralsCoronavirus disease 2019Series of teleconferencesPotential antiviral activityLopinavir-ritonavirCritical illnessDisease physiciansMost patientsSupportive careMembrane oxygenationPediatric patientsAntiviral therapyMild courseSevere illnessIll childrenClinical trialsElectrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation
Friedman DM, Kim M, Costedoat-Chalumeau N, Clancy R, Copel J, Phoon CK, Cuneo B, Cohen R, Masson M, Wainwright BJ, Zahr N, Saxena A, Izmirly P, Buyon JP. Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. Circulation Arrhythmia And Electrophysiology 2020, 13: e008686. PMID: 32907357, PMCID: PMC7668319, DOI: 10.1161/circep.120.008686.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsCardiotoxicityDrug Administration ScheduleDrug MonitoringElectrocardiographyFemaleFetal BloodFetal HeartGestational AgeHeart BlockHeart RateHumansHydroxychloroquineInfantInfant, NewbornMalePredictive Value of TestsPregnancyRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBlood levelsSSA/Ro antibodiesHistorical healthy controlsHydroxychloroquine blood levelsCord blood levelsCongenital heart blockSystemic lupus erythematosusTrimester of pregnancyEfficacy of hydroxychloroquineCoronavirus disease-19Electrocardiographic QT intervalCOVID-19 studiesPostnatal ECGRo antibodiesIndividual pregnanciesLupus erythematosusQTc prolongationAntiviral therapyHeart blockClinical efficacyRheumatic conditionsDrug exposureMaternal useCord bloodDisease-19Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
Chang D, Zhao P, Zhang D, Dong JH, Xu Z, Yang G, Li BY, Liu HX, Li BA, Qin CF, Peng XH, Wang FS, Xie LX, Chen Z, Dela Cruz CS, Sharma L, Qin EQ. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2585-2591.e1. PMID: 32574840, PMCID: PMC7305869, DOI: 10.1016/j.jaip.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBetacoronavirusC-Reactive ProteinChildChild, PreschoolComorbidityCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHumansInfantInflammationInflammation MediatorsInterleukin-6MaleMiddle AgedPandemicsPneumonia, ViralReal-Time Polymerase Chain ReactionRespiration, ArtificialSARS-CoV-2Severity of Illness IndexYoung AdultConceptsDisease severityViral clearanceViral persistenceDisease outcomeCOVID-19Viral presenceExtensive lung involvementC-reactive proteinEffective antiviral therapyCoronavirus disease 2019Severe disease outcomesHost antiviral mechanismsInfectious viral particlesImmunomodulatory therapyInflammatory markersLung involvementRespiratory supportClinical courseAntiviral therapyIL-6Viral reactivationClinical managementInflammatory responseChest imagingDisease 2019Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series
Londeree J, Winterberg PD, Garro R, George RP, Shin S, Liverman R, Serluco A, Romero R, Yildirim I. Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series. Pediatric Transplantation 2020, 24: e13769. PMID: 32558134, DOI: 10.1111/petr.13769.Peer-Reviewed Original ResearchConceptsPediatric SOT recipientsSOT recipientsCase seriesSevere diseasePediatric solid organ transplant recipientsSolid organ transplant recipientsType of allograftMainstay of treatmentOrgan transplant recipientsSeverity of diseaseHuman adenovirus infectionHAdV diseaseHAdV viremiaPediatric recipientsTransplant recipientsHAdV infectionDisease courseAntiviral therapySignificant morbidityDisease presentationUS FDAAdenovirus infectionBrincidofovirDiseaseRecipientsEffect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M, Mourão M, Brito-Sousa J, Baía-da-Silva D, Guerra M, Hajjar L, Pinto R, Balieiro A, Pacheco A, Santos J, Naveca F, Xavier M, Siqueira A, Schwarzbold A, Croda J, Nogueira M, Romero G, Bassat Q, Fontes C, Albuquerque B, Daniel-Ribeiro C, Monteiro W, Lacerda M. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. JAMA Network Open 2020, 3: e208857. PMID: 32330277, PMCID: PMC12124691, DOI: 10.1001/jamanetworkopen.2020.8857.Peer-Reviewed Original ResearchConceptsHigh dosage groupSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionAcute respiratory syndrome coronavirus 2 infectionLow dosage groupSyndrome coronavirus 2 infectionCoronavirus 2 infectionChloroquine diphosphateDay 13COVID-19Phase IIb clinical trialNonsevere COVID-19Secondary end pointsSevere COVID-19High-dose groupSpecific antiviral therapyTertiary care facilityIIb clinical trialCoronavirus disease 2019More heart diseaseParticipants' clinical statusAdjunctive therapyAdult patientsIll patientsPrimary outcomeAntiviral therapyTransplant Adenovirus Infection: Clinical Syndromes, Diagnosis, and Management
Malinis M, Azar M. Transplant Adenovirus Infection: Clinical Syndromes, Diagnosis, and Management. 2020, 1-25. DOI: 10.1007/978-3-030-01751-4_33-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSolid organ transplant recipientsInadequate clinical responseReduction of immunosuppressionCornerstone of treatmentOrgan transplant recipientsSolid organ transplantationManifestations of diseaseDirect antigen detectionGraft dysfunctionGraft lossImmunosuppression reductionTransplant recipientsClinical responseAntiviral therapySignificant morbidityAsymptomatic sheddingTherapeutic optionsViral cultureClinical syndromeAdenoviral diseaseOrgan transplantationHematopoietic stem cellsAntigen detectionAdenovirus infectionInfection
2019
Updates on Chronic HBV: Current Challenges and Future Goals
Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Current Treatment Options In Gastroenterology 2019, 17: 271-291. PMID: 31077059, DOI: 10.1007/s11938-019-00236-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTenofovir alafenamide fumarateGlobal public health problemPublic health problemChronic HBVHepatocellular carcinomaLiver failureCurative treatmentLiver diseaseAntiviral therapyClinical trialsHealth problemsLaboratory safety parametersNew treatment recommendationsAdvanced liver diseaseComplications of cirrhosisCurrent antiviral therapiesEarly phase studiesLong-term useNucleotide analog drugsHBV reactivationLiver decompensationFunctional cureTherapeutic armamentariumTreatment recommendationsImproved outcomes
2018
1901. Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study
Messacar K, Sillau S, Hopkins S, Otten C, Wilson-Murphy M, Wong B, Santoro J, Treister A, Tokhie H, Torres A, Zabrocki L, Glanternik J, Hurst A, Martin J, Schreiner T, Makhani N, DeBiasi R, Kruer M, Tremoulet A, Van Haren K, Desai J, Benson L, Gorman M, Abzug M, Tyler K, Dominguez S. 1901. Safety, Tolerability, and Efficacy of Fluoxetine as an Antiviral for Enterovirus D68 Associated Acute Flaccid Myelitis: A Retrospective Multicenter Cohort Study. Open Forum Infectious Diseases 2018, 5: s546-s546. PMCID: PMC6254028, DOI: 10.1093/ofid/ofy210.1557.Peer-Reviewed Original ResearchAcute flaccid myelitisFluoxetine-treated patientsSerious adverse eventsMulticenter cohort studyEfficacy of fluoxetineEV-D68Cohort studyInitial examinationSevere paralysisRetrospective multicenter cohort studyPoor long-term outcomesAdverse effectsDose of fluoxetinePropensity-adjusted analysisLong-term disabilityLong-term outcomesPotential antiviral therapiesUntreated controlsAdverse eventsMost patientsEfficacy signalsPrimary outcomeAntiviral therapyStudy criteriaEffective therapyDetection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests
Azar MM, Landry ML. Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests. Journal Of Clinical Microbiology 2018, 56: 10.1128/jcm.00367-18. PMID: 29695519, PMCID: PMC6018333, DOI: 10.1128/jcm.00367-18.BooksConceptsRapid influenza diagnostic testsRespiratory syncytial virusNucleic acid amplification testsSyncytial virusB virusInfluenza AClinical Laboratory Improvement AmendmentsAntiviral therapyPoint of careAvailable rapid influenza diagnostic testsSensitive nucleic acid amplification testsMolecular testsInfluenza diagnostic testsRespiratory virus infectionsInfection prevention strategiesRapid antigen detectionRapid laboratory testingViral diagnostic testingDetection of influenzaNew pandemic strainsAccurate laboratory diagnosisRapid antigenRespiratory virusesViral culturePatient managementSolid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients
Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Current Opinion In Organ Transplantation 2018, 23: 257-263. PMID: 29432255, DOI: 10.1097/mot.0000000000000504.Peer-Reviewed Original ResearchConceptsViremic donorsHepatitis CWaitlist mortalityHepatitis C viremic donorsEarly trial dataHCV-negative recipientsTransplantation of graftsHepatitis C therapySolid organ transplantsSolid organ transplantationUtilization of graftsFormal clinical trialsNet overall reductionGraft utilizationNonviremic recipientsTransplant recipientsC therapyNegative patientsAntiviral therapyNegative recipientsTransplantation ratesClinical trialsOrgan poolDonor organsOrgan transplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply